Hanan M Fathi

Prof. Dr. Hanan M Fathi

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2023 in Rheumatology International
Verified
Journal Article
Open access
PDF file
TGTamer A Gheita
Tamer A Gheita
HRHala A. Raafat
Hala A. Raafat
SESamah A. El-Bakry
Samah A. El-Bakry
AEAhmed Elsaman
Ahmed Elsaman
HEHanan M. El-Saadany
Hanan M. El-Saadany
TGThe Egyptian College of Rheumatology (ECR) Rheumatoid Arthritis Study Group
The Egyptian College of Rheumatology (ECR) Rheumatoid Arthritis Study Group
To depict the spectrum of rheumatoid arthritis (RA) in Egypt in relation to other universal studies to provide broad-based characteristics to this particular population. This work included 10,364 adult RA patients from 26 specialized Egyptian rheumatology centers representing 22 major cities all over the country. The demographic and clinical features as well as therapeutic data were assessed. The mean age of the patients was 44.8 ± 11.7 years, disease duration 6.4 ± 6 years, and age at onset 38.4 ± 11.6 years; 209 (2%) were juvenile-onset. They were 8750 females and 1614 males (F:M 5.4:1). 8% were diabetic and 11.5% hypertensive. Their disease activity score (DAS28) was 4.4 ± 1.4 and health assessment questionnaire (HAQ) 0.95 ± 0.64. The rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) were positive in 73.7% and 66.7% respectively. Methotrexate was the most used treatment (78%) followed by hydroxychloroquine (73.7%) and steroids (71.3%). Biologic therapy was received by 11.6% with a significantly higher frequency by males vs females (15.7% vs 10.9%, p = 0.001). The least age at onset, F:M, RF and anti-CCP positivity were present in Upper Egypt (p < 0.0001), while the highest DAS28 was reported in Canal cities and Sinai (p < 0.0001). The HAQ was significantly increased in Upper Egypt with the least disability in Canal cities and Sinai (p = 0.001). Biologic therapy intake was higher in Lower Egypt followed by the Capital (p < 0.0001). The spectrum of RA phenotype in Egypt is variable across the country with an increasing shift in the F:M ratio. The age at onset was lower than in other countries.
1

9 July 2021 in Rheumatology International
Verified
Journal Article
Open access
PDF file
NHNevin Hammam
Nevin Hammam
STSamar Tharwat
Samar Tharwat
RSRawhya R. El Shereef
Rawhya R. El Shereef
AEAhmed M. Elsaman
Ahmed M. Elsaman
NKNoha M. Khalil
Noha M. Khalil
TGTamer A Gheita
Tamer A Gheita
Objectives The aim of the present work was to explore the perspectives of Egyptian Rheumatology staff members as regards the coronavirus disease-19 (COVID-19) vaccine. Methods The survey is composed of 25 questions. Some questions were adapted from the global rheumatology alliance COVID-19 survey for patients. Results 187 rheumatology staff members across Egypt from 18 universities and authorizations actively participated with a valid response. The mean time needed to complete the survey was 17.7 ± 13 min. Participants were 159 (85%) females (F:M 5.7:1). One-third agreed that they will be vaccinated once available, 24.6% have already received at least one dose, 29.4% are unsure while 16% will not take it. Furthermore, 70.1% agreed that they will recommend it to the rheumatic diseases (RD) patients once available, 24.1% are not sure while 5.9% will not recommend it. RD priority to be vaccinated against COVID-19 in descending order include SLE (82.9%), RA (55.1%), vasculitis (51.3%), systemic sclerosis (39.6%), MCTD (31.6%), Behcet's disease (28.3%). The most common drugs to be avoided before vaccination included biologics (71.7%), DMARDs (44.4%), biosimilars (26.7%), IVIg (17.1%) and NSAIDs (9.1%). Conclusions The results of the study and specifically the low rate of acceptability are alarming to Egyptian health authorities and should stir further interventions to reduce the levels of vaccine hesitancy. As rheumatic disease patients in Egypt were not systematically provided with the vaccine till present, making the vaccine available could as well enhance vaccine acceptance. Further studies to investigate any possible side effects, on a large scale of RD patients are warranted.

19 July 2021 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
TGTamer A Gheita
Tamer A Gheita
NHNevin Hammam
Nevin Hammam
SFSamar M. Fawzy
Samar M. Fawzy
EEEiman Abd El‐Latif
Eiman Abd El‐Latif
IEIman I. El‐Gazzar
Iman I. El‐Gazzar
T(the Egyptian College of Rheumatology‐Behçet's Disease Study Group (ECR‐BDSG)
the Egyptian College of Rheumatology‐Behçet's Disease Study Group (ECR‐BDSG)

1 October 2018 in The Egyptian Rheumatologist
Verified
Journal Article
Open access
ASAmira A. Shahin
Amira A. Shahin
HZHania S. Zayed
Hania S. Zayed
RERasha M. Elrefai
Rasha M. Elrefai
HTHeba Taher
Heba Taher
AEAhmed Elsaie
Ahmed Elsaie
MEMervat I. Abd Elazeem
Mervat I. Abd Elazeem

1 July 2017 in The Egyptian Rheumatologist
Verified
Journal Article
Open access
IEIman El-Gazzar
Iman El-Gazzar
AEAl-Hussein El-Dakrony
Al-Hussein El-Dakrony
SSSafaa Sayed
Safaa Sayed
HEHussein El-Fishawy
Hussein El-Fishawy
HFHanan M Fathi
Hanan M Fathi
RRRehab Abdel Rahman
Rehab Abdel Rahman
Aim of the workThe aim of the present work was to assess the effect of metabolic syndrome (MetS) co-morbidity and the carotid intima-media thickness (cIMT) in Behçet’s disease (BD) patients and to study their relation to clinical manifestations and disease activity.Patients and methodsThirty-eight BD patients and another 38 age and sex matched controls were studied. The disease activity was assessed using BD Current Activity Form (BDCAF) score and the adult treatment panel criteria were used to define the presence of MetS. The cIMT was measured by ultrasonographic scanning.ResultsThe BD patients were 30 males and 8 females with a mean age of 36.2±7.8years and disease duration of 7.6±5.1years. MetS was more frequent in BD patients (28.9%; 7 males and 4 females) compared to the control (10.5%; 2 males and 2 females). The mean IMT in the patients (0.78±0.32mm) was significantly increased compared to the control (0.42±0.12mm) (p<0.001). The IMT was thickened in 9 (23.7%) patients and atherosclerotic plaques present in 6 (15.8%) with MetS. The IMT and BDCAF tended to be increased in those with MetS compared to those without. The IMT in the BD patients significantly correlated with the BDCAF (r=0.47, p=0.003), serum creatinine (r=0.33, p=0.04), urea (r=0.53, p=0.001) and triglycerides (r=0.45, p=0.005). The IMT tended to be increased in the male patients.ConclusionMetabolic syndrome is an important co-morbidity in BD patients and measuring the IMT is essential to avoid an increase in flares or the consequent development of cardiovascular diseases or renal impairment

1 January 2019 in The Egyptian Rheumatologist
Verified
Journal Article
Open access
IEIman I. El-Gazzar
Iman I. El-Gazzar
SISoha E. Ibrahim
Soha E. Ibrahim
WEWael S. El-Sawy
Wael S. El-Sawy
HFHanan M Fathi
Hanan M Fathi
AEAmal H. Eissa
Amal H. Eissa